CLRB - Company ID 0001279704
The table below shows Cellectar Biosciences, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$23.12M | -$47.58M | -$32.38M | -$25.22M | -$22.57M | -$13.93M |
| Capital expenditure | $5.88K | $104.19K | $864.04K | $225.97K | $141.36K | $62.35K |
| Investing cash flow | -$5.88K | -$104.19K | -$864.04K | -$225.97K | -$141.36K | -$62.35K |
| Dividends paid | - | - | - |
Cellectar Biosciences, Inc. reported operating cash flow of -$23.12M for fiscal year 2025. That is up 51.4% from -$47.58M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$8.28M (FY 2016) to -$23.12M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $13.03M | $61.41M | $22.94M | $9.61M | $1.25M | $60.55M |